In infertility patients receiving CC/HMG, premature LH surge occurred in 21.6% with incremental cetrorelix versus 18.9% with the high-dose protocol.
In plain wordsIn infertility patients receiving CC/HMG, premature LH surge occurred in 21.6% with incremental cetrorelix versus 18.9% with the high-dose protocol.
- Peptide
- Cetrorelix
- Outcome
- IncreasePremature LH surge
- Study
n: not reported in source
- Comparator
- Cetrorelix 0.5 mg daily from leading follicle diameter 14 mm
- Analysis
- Primary
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 0.25 mg daily increased to 0.5 mgAs given in this study (human).
Measurements
- Premature LH surge
- 21.6%
- protocol A, incremental cetrorelix 0.25 to 0.5 mg
- Premature LH surge
- 18.9%
- protocol B, cetrorelix 0.5 mg
Source sentences
Premature LH surge occurred in 21.6% of patients undergoing protocol A, and in 18.9% of patients undergoing protocol B.
5 context sentences(design, population, supporting numbers)
Couples with male factor or unexplained infertility who were going to undergo intrauterine insemination were randomized into two stimulation protocols.
All women were stimulated with CC and HMG.
In protocol A, cetrorelix was given at 0.25 mg per day when the leading follicles reached 14 mm, and increased to 0.5 mg when the leading follicles were 16 mm.
With protocol B, cetrorelix was given at 0.5 mg per day when the leading follicles reached 14 mm.
The primary outcome measure was the incidence of premature LH surge.